C Terminal Variants of FSH Receptor
|ClinicalTrials.gov Identifier: NCT01524588|
Recruitment Status : Completed
First Posted : February 2, 2012
Last Update Posted : October 22, 2012
Follicle-stimulating hormone (FSH) is used in medically assisted procreation, to induce an ovarian stimulation in women. However, the FSH dose that has to be injected is quite hard to adjust, because an excess of exogenous hormone could lead to very severe complications for patient. This hormone acts on its cognate receptor, the FSHR, present on the granulosa cells surface, and which regulation involve the intra-cytoplasmic carboxy-terminus domain.
The investigators first aimed to research in the c-terminus part of the receptor the presence of allelic variants that could explain the variations of response to FSH stimulation.
The investigators also would want to complete the data already known on a functionally determinant single nucleotide polymorphism on 680 position in the c-terminus part of the hFSHR.
Then, the investigators would analyze the entire sequence of the hFSHR of patients presenting an unusual phenotype in response to FSH treatment, in order to detect a potential mutation involved in the receptor functionality.
The results of this study could allow us to increase our knowledge on the hFSHR physiology and functionality, in order to adjust treatment to the genetic profile of patients.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||814 participants|
|Official Title:||C Terminal Peptide Variants of the Fsh Receptor in Women Involved in an Assisted Reproduction Programm : Mechanistic Approach|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||April 2011|
|Actual Study Completion Date :||April 2011|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01524588
|CHRU de Tours|
|Tours, France, 37000|
|Principal Investigator:||Dominique ROYERE||Tours Hospital|